A volunteer dies in an AstraZeneca Covid-19 vaccine trial in Brazil

Elias Hubbard
October 22, 2020

A volunteer in Brazil's trial of AstraZeneca's experimental coronavirus vaccine has died, the Brazilian health agency Anvisa announced on Wednesday, but organizers said there was no reason to stop the trial - an indication that the death is not linked to the vaccine.

"We are writing to let you know that the USA drug regulatory authority (Food and Drug Administration or FDA) has also now completed their analysis of the information relating to the participants concerned and has come to the same conclusion as the other drug regulators including the MHRA", the United Kingdom's Health Research Authority said in a letter, according to the publication.

Dr Feitosa has already been treating COVID-19 patience ever since March and was working in the emergency rooms as well as the intensive care units at two different hospitals located in Rio Janeiro, according to Globo. Oxford has no concerns about the safety of the vaccine trial after an independent and careful review, and Brazil's regulators have recommended that it continue, university communications head Stephen Rouse said in statement.

In a statement to NBC News, AstraZeneca said the trial will continue.

According to Reuters, AstraZeneca plans to resume its trial sometime this week.

The statement said that they can not give any comment regarding the individual cases in the known ongoing trial of the said Oxford vaccine but they do adhere strictly to the medical confidentiality as well as the clinical trial regulations.

The volunteer was Brazilian and was taking part in the trials at The Federal University of Sao Paolo, the Mirror reports.

AstraZeneca shares fell 1.8 per cent.

Brazil's federal government has plans to purchase the United Kingdom vaccine and produce it at FioCruz in Rio de Janeiro, while a competing vaccine from China's Sinovac Biotech Ltd is being tested by Sao Paulo state's research center Butantan Institute.

For more coronavorus updates follow our live blog.

Other reports by Click Lancashire

Discuss This Article